Your shopping cart is empty

Subscriber login

REGISTER FOR FREE EZINES

Advanced Search

Home
Books
Conferences
DVDs
Newsletters
Form 483s
Pharma Quality Advisor
Webinar Training Pass
White Papers
Advertising/Sponsorships
About Us

E-Zines

Check out our free and informative ezines and sign up now

Home > Newsletters > FDAnews Drug Daily Bulletin > Sanofi, Regeneron Commence Patient Recruitment in Phase III CVOT

FDAnews Drug Daily Bulletin

Nov. 7, 2012 | Vol. 9 No. 219

Sanofi, Regeneron Commence Patient Recruitment in Phase III CVOT

Sanofi and Regeneron Pharmaceuticals have commenced patient recruitment in a Phase III cardiovascular outcomes trial (CVOT) to test SAR236553/REGN727, designed to lessen low-density lipoprotein cholesterol levels.
Pharmaceutical Business Review

Register Now
Print This Page
Email This Article
RSS
Archives

Related Articles

Full Issue Shionogi Gets Untitled Letter After Refusing To Conduct Postmarketing Study EU Traceability Requirements for Advanced Therapies Need Tweaking, Pfizer Says Editor's Note

Home
Advertising/Sponsorships
About Us
Contact Us
Site Map
Privacy Policy

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.

ePublishing :: CMS, Hosting & Web Development | © Copyright by FDAnews

All rights reserved. Do not duplicate or redistribute in any form.